A5047280933- HER2/EGFR in Cancer Research
- Cancer, Lipids, and Metabolism
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- Cancer, Hypoxia, and Metabolism
- Monoclonal and Polyclonal Antibodies Research
- Inflammatory mediators and NSAID effects
- Peroxisome Proliferator-Activated Receptors
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Cancer Diagnosis and Treatment
- Estrogen and related hormone effects
- Glycosylation and Glycoproteins Research
- Radiopharmaceutical Chemistry and Applications
- Gastric Cancer Management and Outcomes
- Lung Cancer Research Studies
- Cancer survivorship and care
- Economic and Financial Impacts of Cancer
- Medical Imaging Techniques and Applications
- PI3K/AKT/mTOR signaling in cancer
- Immunotherapy and Immune Responses
- Inflammatory Biomarkers in Disease Prognosis
Spanish National Cancer Research Centre
2012-2025
Roche (Spain)
2006-2024
Hospital Universitario de La Princesa
2015-2024
Universidad Autónoma de Madrid
2018-2024
Sociedad Española de Oncología Médica
2012-2021
Centro de Investigación del Cáncer
2012-2020
Centro Nacional de Epidemiología
2020
McGill University Health Centre
2019
Georgetown University
1990-2018
Centre Antoine Lacassagne
2017-2018
Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is poor and more effective treatments are urgently needed. We have evaluated the efficacy erlotinib in this setting its association activating mutations epidermal growth factor receptor (<i>EGFR</i>) gene. retrospectively identified NSCLC treated erlotinib. <i>EGFR</i> exons 19 21 were analysed by direct sequencing. Efficacy tolerability compared according to mutational status. 69 identified, 17 whom...
<h3>Importance</h3> Efficacious ERBB2 (formerly HER2 or HER2/neu)-directed treatments, in addition to trastuzumab and lapatinib, are needed. <h3>Objective</h3> To determine whether neratinib, an irreversible pan-ERBB tyrosine kinase inhibitor, plus paclitaxel improves progression-free survival compared with the first-line treatment of recurrent and/or metastatic ERBB2-positive breast cancer. <h3>Design, Setting, Participants</h3> In randomized, controlled, open-label NEfERT-T trial conducted...
BackgroundAnti-HER2 therapies are associated with a risk of increased cardiac toxicity, particularly when part anthracycline-containing regimens. We report safety pertuzumab, trastuzumab, and chemotherapy in the neoadjuvant treatment HER2-positive early breast cancer.Patients methodsBERENICE (NCT02132949) is nonrandomized, phase II, open-label, multicenter, multinational study patients normal function. In period, cohort A received four cycles dose-dense doxorubicin cyclophosphamide, then 12...
Fatty acid synthase (FAS) activity is a potential therapeutic target to treat cancer and obesity. Here, we have identified molecular link between FAS HER2 ( erb B-2) oncogene, marker for poor prognosis that overexpressed in 30% of breast ovarian cancers. Pharmacological inhibitors cerulenin C75 were found suppress p185 oncoprotein expression tyrosine-kinase overexpressors. Similarly, was dramatically down-regulated when gene silenced by using the highly sequence-specific mechanism RNA...
The erb B2 oncogene encodes a 185-kilodalton transmembrane protein whose sequence is similar to the epidermal growth factor receptor (EGFR). A 30-kilodalton (gp30) secreted from MDA-MB-231 human breast cancer cells was shown be ligand for p185 . An antibody EGFR abolished tyrosine phosphorylation induced by EGF and transforming factor-α (TGF-α) but only partially blocked that produced gp30 in SK-BR-3 cells. In two cell lines overexpress do not express (MDA-MB-453 Chinese hamster ovary line...
Abstract. Objectives : More than 50 years ago, we learned that breast cancer cells (and those of many other types tumour) endogenously synthesize 95% fatty acids (FAs) de novo , despite having adequate nutritional lipid supply. Today, know benefit from this phenomenon in terms enhanced cell proliferation, survival, chemoresistance and metastasis. However, the exact role major lipogenic enzyme acid synthase (FASN) as cause, correlate or facilitator remains unidentified. Materials methods To...
A low incidence of breast cancer in the Mediterranean basin suggests that a high consumption Extra Virgin Olive Oil (EVOO) might confer this benefit. While anti-HER2 oncogene effects main ω-9 fatty acid present EVOO triacylglycerols (i.e., oleic acid) have been recently described, anti-breast activities non-glyceridic constituents -which consist at least 30 phenolic compounds-, remained to be evaluated. Semi-preparative HPLC was used isolate polyphenols tyrosol, hydroxytyrosol, oleuropein)....
This study examined the impact of Recurrence Score (RS) in Spanish breast cancer patients and explored associations between clinicopathological markers likelihood change treatment recommendations.
Next Generation Sequencing (NGS) panels are increasingly used in advanced patients with cancer to guide therapy. There is, however, controversy about when should these be used, and their impact on the clinical course.In an observational study of 139 having NGS test [from January 1st, 2017 December 30th, 2020, two hospitals (Hospital Universitario de La Princesa Hospital Quironsalud Madrid) from Spain], we evaluated whether course (progression-free survival, PFS) was influenced by drug-based...
PURPOSE It has been suggested that age is associated with chemotherapy-related death in patients non-Hodgkin's lymphoma (NHL) treated doxorubicin-containing chemotherapy. The purpose of this study was to evaluate the relative influence increasing and other clinical parameters on occurrence treatment-related elderly intermediate- or high-grade NHL cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) METHODS A retrospective 60 years older CHOP chemotherapy a single cancer center....
Chemokines are implicated in tumor pathogenesis, although it is unclear whether they affect human cancer progression positively or negatively. We found that activation of the chemokine receptor CCR5 regulates p53 transcriptional activity breast cells through pertussis toxin-, JAK2-, and p38 mitogen-activated protein kinase-dependent mechanisms. blockade significantly enhanced proliferation xenografts from bearing wild-type p53, but did not a mutation. In parallel, data obtained primary...
Several randomized trials have tested the use of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage (GMCSF) in relieving chemotherapy-induced bone marrow suppression. However, CSFs treatment neutropenic fever remains virtually unexplored. This study evaluated benefits adding CSF therapy to standard antibiotic treatments given cancer patients for fever. The usefulness was quantified terms reducing following: ( a ) duration neutropenia, b length hospitalization, c overall...
Abstract Purpose: To evaluate the efficacy of treatment with aromatase inhibitor letrozole in breast cancer patients segregated respect to DNA polymorphisms gene CYP19. Patients and Methods: Postmenopausal (n = 67) hormone receptor–positive metastatic were treated letrozole. PCR allelic discrimination was used examine three single-nucleotide (SNP) obtained from carcinoma tissue. Two SNPs analyzed (rs10046 rs4646) located 3′ untranslated region one (rs727479) intron CYP19 gene. The primary...
The importance of the extent metastatic disease in circulating levels CA 15-3 and carcinoembryonic antigens (CEA) was studied 173 patients with advanced breast carcinoma. Estimates were obtained by an objective arbitrary scale. Patients observed clinically after serum samples obtained, survival recorded. Elevated values (greater than 40 U/ml) seen 130 CEA 5 ng/ml) 97 cases (75% versus 56%, P less .0001). correlated estimated (P .0001), number metastases = .0006), from study entry .01). but...